Related Experiment Video

Updated: Nov 30, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.1K

Anticoagulation in Patients with Heart Failure and Sinus Rhythm

Xiao Li1, Jingmin Yang1, Danyan Xu1

  • 1Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University.

International Heart Journal
|November 16, 2020
PubMed

Insights

Prophylactic anticoagulant therapy does not improve clinical outcomes for heart failure patients in sinus rhythm. While some studies suggest a reduced stroke risk, increased bleeding risk and negative primary endpoint results indicate no overall benefit for anticoagulation in this patient group.

Area of Science:

  • Cardiology
  • Thrombosis Research
  • Clinical Pharmacology

Background:

  • Patients with heart failure (HF) face elevated risks of thromboembolic events, even without atrial fibrillation.
  • The efficacy of prophylactic anticoagulation in HF patients maintaining sinus rhythm remains uncertain.

Purpose of the Study:

  • To review evidence on anticoagulation for heart failure patients in sinus rhythm.
  • To determine if prophylactic anticoagulation benefits clinical outcomes in this population.

Main Methods:

  • Retrospective review of pathophysiological mechanisms.
  • Analysis of epidemiological studies and clinical trials.
  • Examination of subgroup analyses regarding stroke and bleeding risks.

Main Results:

  • Subgroup analyses indicated potential stroke risk reduction with anticoagulation, but with significantly increased bleeding risk.
  • Clinical trials consistently reported negative results for primary endpoint outcomes.
  • Overall, prophylactic anticoagulation demonstrated no improvement in clinical outcomes for HF patients in sinus rhythm.

Conclusions:

  • Anticoagulant therapy does not enhance clinical outcomes in heart failure patients with sinus rhythm.
  • The increased bleeding risk outweighs any potential benefits in this patient group.
  • Further research may be needed to identify specific subgroups that could benefit from anticoagulation.

Keywords:
DabigatranRivaroxabanWarfarin

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.7K
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

3.9K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
127
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
148
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
109
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
965